FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News

Suggestions for Investigator Safety Reporting Guidance

Two stakeholders make suggestions for changes to an FDA draft guidance on investigator responsibility for safety reporting for investigational drugs a...

Human Drugs

Panel Mixed Vote on Mercks Covid Drug

FDAs Antimicrobial Drugs Advisory Committee narrowly votes 13-10 to recommend an emergency use authorization for Mercks oral antiviral molnupiravir fo...

Human Drugs

Teleflex Recalls Percutaneous Thrombolytic Device

Teleflex recalls its Arrow-Trerotola Over-The-Wire Percutaneous Thrombolytic Device Kit, 7FR, after receiving reports about the inner lumen becoming d...

Human Drugs

AstraZeneca, Merck sNDA for Lynparza

FDA accepts for priority review an AstraZeneca and Merck supplemental NDA for Lynparza (olaparib) for the adjuvant treatment of patients with BRCA-mut...

Medical Devices

Attorneys See Questions in LDT Policy Change

Three Hyman, Phelps attorneys say an HHS announcement withdrawing a Trump administration policy on FDA review of laboratory-developed tests leaves man...

Human Drugs

Fennec Pharma Hit with 2nd Complete Response

FDA sends Fennec Pharmaceuticals a second complete response letter on its NDA for Pedmark (sodium thiosulfate, intravenous) for preventing ototoxicity...

Federal Register

Nominations for Radiation Safety Standards Panel

Federal Register notice: FDA requests nominations for voting members to serve on CDRHs Technical Electronic Product Radiation Safety Standards Committ...

Federal Register

Real-World Data Guidance on Using Registries

Federal Register notice: FDA makes available a draft guidance on Real-World Data: Assessing Registries to Support Regulatory Decision-Making for Drug ...

Human Drugs

Comments on FDA Real-World Data Guidance

Drug companies and other stakeholders respond to an FDA draft guidance on using electronic health records and claims data in real-world data studies.

Federal Register

Regulatory Review Period for Zepzelca

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Pharma Mars Zepzelca (lurbinectedin).